Figure 5.
Imatinib reduces liver and lung injury in TSLP-Tg mice. Representative liver and lung sections stained with H & E of a control TSLP-Tg mouse and an imatinib-treated TSLP-Tg mouse receiving 4 wk of treatment beginning at age day 90. Imatinib dramatically reduces portal inflammatory cell infiltrates and lung infiltrates.